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ABSTRACT
Rationale: Nicotine is the addictive component in cigarettes which maintains cigarette smoking
that subsequently leads to morbidity and mortality. There are growing regulatory efforts to lower
the nicotine content in cigarettes so that they are minimally addictive. Valid methods for
assessing the abuse liability of cigarettes are essential to these efforts. While subjective effect
measures and hypothetical purchase tasks are appealing because they are far easier to administer,
it is unclear whether these methods can be used to evaluate acute relative reinforcing, a critical
component of abuse liability. This secondary analysis sought to evaluate the utility of one
subjective effects measure, the modified Cigarette Evaluation Questionnaire (mCEQ), and one
hypothetical purchase task, the Cigarette Purchase Task (CPT), for predicting acute relative
reinforcing efficacy as measured by concurrent choice Self-Administration (SA)
Method: Current smokers (N=169) belonging to one of three vulnerable populations
(socioeconomically disadvantaged women of childbearing age, opioid-maintained individuals, or
individuals with affective disorders) participated in a multi-site, double blind study evaluating
research cigarettes with varying levels of nicotine content (0.4, 2.4, 5.2, 15.8 mg/g). In Phase 1 (4
sessions, 1 research cigarette per session) participants completed the mCEQ and CPT following
ad-lib smoking of the research cigarette. In Phase II (6 sessions) cigarette preference was
assessed using two-dose concurrent choice tests. Difference scores were calculated for each of
the five mCEQ subscales and five CPT indices for all six possible dose comparisons evaluated in
Phase II. We evaluated the utility of the mCEQ subscale and CPT index difference scores for
predicting preference for the higher dose in a given dose comparison using a mixed-model of
repeated measures analysis of variance. Finally, we used stepwise regressions to determine
which subscales and indices served as independent predictors of concurrent choice SA.
Results: Among mCEQ subscales, higher Satisfaction and Enjoyment of Respiratory Tract
Sensation were independently predictive of higher dose preference in the choice testing regardless
of dose comparison. There was a significant Satisfaction X Vulnerable Population interaction
where increases in Satisfaction difference scores corresponded to greater changes in higher dose
preference among socioeconomically disadvantaged women of childbearing age compared to
other Vulnerable Populations. Among CPT indices, Elasticity was the only independent predictor
of choice. However, there was a significant Elasticity X Dose Comparison X Vulnerable
Population interaction associated with its predictive utility where the relationship between
elasticity and choice differed by dose among opioid-maintained individuals. In a final model,
including all subscales and indices, Satisfaction and Enjoyment of Respiratory Tract Sensations
remained the only significant predictors of choice.
Discussion: Concurrent choice testing, subjective effects and hypothetical purchase tasks capture
some common features of abuse liability. Concurrent choice testing and the Satisfaction subscale
were the most concordant measures. The observation that CPT indices are not robust predictors
of choice in a concurrent arrangement suggests this measure may have greater utility for
capturing individual differences as opposed to isolating the acute relative reinforcing effects of
nicotine. Nevertheless, all three measures can contribute to efforts to assess the abuse liability of
cigarettes varying in nicotine dose and important work aimed at regulating these products to
improve human health.
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CHAPTER 1: INTRODUCTION
1.1. Public Health Impact of Cigarette Smoking
Nearly half a million Americans die every year from cigarette smoking-related
diseases (U.S. Department of Health and Human Services [USDHHS], 2014). The most
recent Surgeon General’s report concluded that cigarette smoking causes numerous
cancers, poor cardiovascular health, adverse reproductive health outcomes, respiratory
dysfunction as well as diabetes and eye diseases (USDHHS, 2014). Smoking-related
health problems cost an estimated $300 billion dollars annually (USDHHS, 2014; Xu,
Bishop, Kennedy, Simpson & Pechacek, 2015). Despite the wide array of risks and
substantial costs, about 15% of Americans are current cigarette smokers (Center for
Disease Control and Prevention, 2016).
Cigarettes contain over 5,000 constituents; so far, 93 have been identified as
harmful or potentially harmful and subsequently categorized as a carcinogen, a
cardiovascular toxicant, a reproductive or developmental toxicant, a respiratory toxicant
and/or addictive (Food and Drug Administration [FDA], 2012; Talhout, Schulz, Florek,
van Benthem, Wester & Opperhuizen, 2011; Royal College of Physicians, 2016). The
single constituent that drives persistent use of cigarettes is nicotine (USDHHS, 1988;
2014). Indeed, thirty years ago, the Surgeon General’s report concluded that “nicotine is
the drug in tobacco that causes addiction” (USDHHS, 1988). Importantly, the dose of
nicotine obtained from smoking a cigarette influences the addictiveness of the product
(Benowitz & Henningfield, 1994, Boren, Stitzer & Henningfield, 1990, Donny et al.,
2015, Higgins et al., 2017a, Higgins et al., 2017b, Perkins, Grobe, Caggiula, Wilson &
Stiller, 1996, Perkins, Kunkle, Michael, Karelitz & Donny, 2016, Shahan et al., 1999).
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The morbidity and mortality related to cigarette smoking can be conceptualized as a side
effect of nicotine addiction (Henningfield, 2014). To address this persistent and harmful
behavior, public health interventions should target nicotine and its addictive properties.
In a recent commentary in The New England Journal of Medicine, the current Food and
Drug Administration Commissioner and the Director of the Center for Tobacco Products
within the Food and Drug Administration declared their intention to shape a regulatory
framework to eliminate the use of combustible tobacco products (mainly cigarettes) by
targeting nicotine (Gottlieb & Zeller, 2017). Consistent with this report, on March 15th,
2018, Commissioner Gottlieb issued an advance notice of proposed rulemaking to lower
nicotine in cigarettes to a minimally or non-addictive level (Tobacco Product Standard
for Nicotine Level of Combusted Cigarettes, 2018).
1.2. Reducing Nicotine in Cigarettes
For decades, research has shown that reducing the amount of nicotine obtained
from a cigarette reduces its addictiveness (Benowitz & Henningfield, 2013; Boren et
al., 1990; Donny et al., 2015; Shahan et al., 1999). The two main approaches to
reducing the amount of nicotine obtained from smoking have been reducing the
nicotine yield and reducing the content.
1.2.1. Reducing Nicotine Yield. Early efforts to reduce the amount of nicotine
smokers obtained from each cigarette attempted to do so by lowering the nicotine yield of
a cigarette by altering its physical structure (i.e., increasing the number of holes in the
filter). While the tobacco in the cigarette was the same, it was thought that smokers
would obtain less nicotine because more would escape through the filter holes before
reaching the smoker. These modified cigarettes were introduced to the market in the
2

1970s and advertised as “light” cigarettes. While they are perceived to have lower risks,
studies indicate levels of exposure are comparable between “light” and “full flavor”
cigarettes (Benowitz et al., 1983; Benowitz et al., 1986; Yong et al., 2016) as the reduced
nicotine yield of light cigarettes is easily overcome by a smoker if he/she alters how they
hold their cigarette (e.g., blocking the filter holes with their lips or fingers). Nicotine
yield, therefore, does not necessarily correspond to the delivered dose (Kozlowski &
O’Connor, 2002; Strasser, Ashare, Kozlowski, & Pickworth, 2005).
1.2.2. Reducing Nicotine Content. Another way to decrease the nicotine dose is
to lower the nicotine content of a cigarette by manipulating how much nicotine is in that
cigarette. Historically, this was done by mixing regular nicotine content tobacco with
some portion of nicotine-free tobacco (e.g., Boren et al., 1990). More recently, varying
nicotine concentrations are achieved by genetically modifying tobacco (e.g., Donny et al.,
2015). This new method has helped accelerate research testing the long-standing
hypothesis that there is a so-called nicotine dose threshold for cigarette addiction
(Benowitz & Henningfield, 1994).
In their influential New England Journal of Medicine commentary, Benowitz and
Henningfield (1994) hypothesized that reducing nicotine content to levels less than 0.7
milligrams of nicotine per gram of tobacco (mg/g) could render cigarettes less addictive
with the potential to decrease cigarette use and dependence. They based this dose on the
nicotine intake of cigarette smokers who smoked infrequently and self-reported no
withdrawal when they abstained from smoking. Currently, the nicotine content of most
commercially available cigarettes ranges from 13.5-19.5 mg/g (MacGregor et al., 2014;
Malson, Sims, Murty & Pickworth, 2001). Cigarettes which fall below commercially
3

available levels of nicotine are referred to as reduced nicotine content (RNC) cigarettes.
Cigarettes which fall below Benowitz and Henningfield’s threshold are referred to as
very low nicotine content (VLNC) cigarettes or, in some cases, denicotinized cigarettes.
Another factor that
has focused more scientific
attention on RNC cigarettes
is the signing of the Family
Smoking Prevention and
Tobacco Control Act in 2009
by President Obama (Figure
1-1). This piece of
legislation gave the FDA the
ability to reduce, but not
eliminate, the nicotine in
cigarettes. Now that nicotine content regulation is within the scope of the FDA’s
authority, testing Benowitz & Henningfield’s hypothesis is more critical than ever as
results will influence regulatory policy being formulated right now.
A growing body of literature indicates that lowering the nicotine content in
cigarettes renders cigarettes less addictive and decreases cigarette consumption and
thereby toxicant exposure over extended periods of time (Benowitz et al., 2007; Benowitz
et al., 2012; Donny et al., 2015; Hatsukami et al., 2010; Hatsukami et al., 2017; Higgins
et al., 2017a; Higgins et al., 2017b). In a recent randomized controlled trial published in
The New England Journal of Medicine, smokers who were not trying to quit and who
4

received VLNC cigarettes free of charge for 6 weeks smoked 30% fewer cigarettes per
day at the end of the study compared to those who received normal nicotine content
cigarettes (16 vs. 22 cigarettes per day, respectively; Donny et al., 2015). Consistently
with this, smokers assigned to VLNC cigarettes had lower nicotine exposure. Finally,
participants who received VLNC cigarettes were more likely to report making a quit
attempt in the 30 days after completing the study. While this study is the largest and most
rigorous to date, there are other long-term exposure studies reporting similar outcomes
(e.g., Benowitz et al., 2007; Hatsukami et al., 2013a; Hatsukami et al., 2017).
Given increasing interest, methods for assessing the addictiveness of cigarettes
varying in nicotine content are essential for predicting how these products are used
among various populations of interest, in contexts when alternative sources of nicotine
are available or when these products are used in conjunction with other compounds or
drugs. Methods for assessing the addictive properties of nicotine-containing products are
outlined below, with a focus on behavioral measures, specifically self-administration, and
self-report measures, specifically subjective effect measures and hypothetical purchase
tasks.
1.3. Measuring the Addictive Properties of Drugs
1.3.1. Behavioral Assessments. Addiction is characterized, in part, by high rates
of drug seeking and use. In this conceptualization, an objective, behavioral proxy for
the addictiveness of a drug is its reinforcing properties, or its ability to follow a
behavior and increase the frequency of that behavior in the future (Schuster &
Thompson, 1969). Therefore, reinforcing properties of a drug, in part, predicts the
abuse liability of a drug. To better understand the addictiveness of a given drug, its
5

reinforcing properties can be studied preclinically and in human laboratory studies
using SA experiments (Griffiths, Bigelow & Ator, 2003), whereby the delivery of a
drug is contingent upon a certain operant behavior (e.g., clicking a computer mouse or
pressing a lever a given number of times to earn puffs on a cigarette). While
reinforcing effects measured by SA may not provide a comprehensive analysis of the
abuse liability of a drug (see review by Johnson & Bickel, 2000), it has been argued
that the reinforcing effects of a drug may be the most predictive facet of abuse liability
(see review by Fischman & Foltin, 1991). Consistent with this, SA outcomes are
predictive of drug use patterns outside of a laboratory setting (see reviews by Comer,
Ashworth, Foltin, Johanson, Zacny & Walsh, 2008; Haney & Spealman, 2008).
To directly observe drug taking behavior within a laboratory session, there are
often special logistical and time considerations (see review by Panlilio & Goldberg,
2007). First, SA experiments typically take place over multiple sessions to allow for
multiple exposures to the drug. Furthermore, sessions may run for many hours,
depending on the psychopharmacology of the drug of interest. Finally, to ensure
controlled drug delivery, special facilities and equipment are often required (e.g.,
smoking topography devices, rooms with ventilation for smoking). The benefits of
using such a paradigm, however, is that it allows researchers to isolate the reinforcing
effects of a drug and to evaluate how numerous factors influence drug taking.
There are multiple SA arrangements to assess reinforcing value. Different SA
arrangements can provide different insights into drugs of abuse and how their
reinforcing effects may be influenced. First, drugs can be self-administered at a fixed
rate (FR) of reinforcement (e.g., drug delivery after every 10 lever presses). The
6

Response Rate or the amount of drug earned is a proxy for the reinforcing value of the
drug. Second, progressive ratio (PR) schedules can also be used to assess
reinforcement. PR schedules require a subject to emit an operant on a ratio schedule of
reinforcement that increases every time the drug is earned. When the demand of the
schedule is too high, the subject ceases responding. The highest ratio response
completed by the subject is referred to as the Breakpoint and is also a measure of the
reinforcing effects of the drug. Third, relative reinforcing effects can also be measured
with concurrent choice SA tasks, where two or more schedules of reinforcement are
available at the same time. Concurrent choice SA tasks can include any combination of
schedules of reinforcement (e.g., FR, PR). In this paradigm, relative reinforcing value
can be captured by how often a given reinforcer is chosen in proportion to all choices
made (Preference). In all SA paradigms, researchers can isolate factors which
influence drug taking (e.g., dose, schedule of availability, and availability of other
reinforcers like money, food and other drugs) to evaluate conditions which influence
abuse liability. Broadly speaking, Response Rate, Breakpoint and Preference represent
a laboratory-derived measure of a drug’s relative reinforcing efficacy which at least
partially corresponds to the drug’s abuse liability.
1.3.1.1. Self-administration cigarettes that vary in nicotine content.
Cigarettes with varying levels of nicotine have been assessed in several SA paradigms.
When a dose is assessed in isolation, at a fixed rate and in the presence of an alternative
non-drug reinforcer (i.e., money), SA does not differ across doses (Shahan, Bickel,
Badger & Giordano, 2001). Similarly, when tested in isolation under a PR schedule,
cigarettes with low levels of nicotine show similar Breakpoints to cigarettes with higher
7

doses (Rusted, Mackee, Williams & Willner, 1998; Shahan et al., 1999; Shahan et al.,
2001). Therefore, when tested separately, it appears that cigarettes with varying dose
levels do not differ in their reinforcing properties. However, when two doses are
concurrently available, numerous studies have shown that subjects show clear
preference for cigarettes with more nicotine, even under double-blind conditions
(Boren et al., 1990; Higgins et al., 2017a; Higgins et al., 2017b; Perkins et al., 1996;
Perkins, Kunkle, Michael, Karelitz & Donny, 2016; Shahan et al., 1999). Thus, the
more sensitive behavioral method for the relative abuse liability of cigarettes with
varying doses is with a concurrent choice paradigm where two cigarettes are
simultaneously available for self-administration, a finding consistent with early
research conducted with non-drug reinforcers (Catania, 1963). However, while SA
procedures are considered by some to be the gold standard for assessing abuse liability
(Griffiths, Bigelow & Ator, 2003), they often require substantial time and labor.
Additionally, SA has been criticized for being an oversimplified method for assessing
abuse liability.
1.3.2. Self-Report Measures. While self-report measures are not direct
assessments of drug taking behavior, they require considerably less time and labor. Two
types of self-report measures, subjective effect measures and the more recently
developed, hypothetical purchase tasks, have been used to characterize the abuse liability
of various drugs (Jacobs & Bickel, 1999, see review by Fischman & Foltin, 1991).
1.3.2.1. Subjective effects. Subjective effect measures are a long-standing and
widely used method for assessing different mood states or sensations which may or may
not accompany the administration of a given drug or dose of a drug. Generally, early
8

observations found that positive moods or sensations (e.g., euphoria) were more
frequently documented when assessing drugs which had greater addiction risk (see
review by Fischman & Foltin, 1991). Subjective effect measures are easily captured after
a single exposure to a drug.
To assess subjective effects of drugs, typically before and immediately following
exposure to a given drug or dose of a drug, participants indicate whether a given state or
sensation is present or absent or are asked to assign a score to indicate how severe a given
state or sensation is on the scale provided (e.g., Likert, visual analog scale). Items can be
analyzed individually or can be empirically grouped together to create specific subscales
(e.g., Aversion subscale made up of individual items of dizziness and nausea).
Subjective effect scales are often tailored to capture drug-class specific effects (e.g.,
“limp or loose” for sedatives, “shaky or jittery” for stimulants) and can include items to
evaluate effects associated with routes of administration as well (e.g., assessing throat
“hit” for a cigarette, Griffiths et al., 2003; Jones, Garret & Griffiths, 1999; Rush, Frey &
Griffiths; 1999). Subjective effect measures can capture drug effects and conditioned
drug sensory effects, all of which contribute to the reinforcing properties of a drug
(Rupprecht et al., 2015). Furthermore, subjective effects may also distinguish positively
and negatively reinforcing effects from one another.
1.3.2.1.1. Subjective effects of cigarettes that vary in nicotine content.
Subjective effect measures are commonly used in studies assessing cigarettes with
varying levels of nicotine (Benowitz, Jacob & Herrera, 2006; Boren et al., 1990;
Butschky, Bailey, Henningfield & Pickworth, 1995; Gross, Lee & Stitzer, 1997;
Hatsukami et al., 2013a; Higgins et al., 2017a; 2017b; Perkins et al., 1996; 2016; Shahan
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et al., 1999). While numerous scales have been used to assess subjective effects, there are
common effects which emerge across measures and reports on cigarettes with varying
levels of nicotine. Enjoyment, Flavor/Taste, Liking, Satisfaction and Strength are
common positive subjective effects which increase as a function of the nicotine dose
delivered by a cigarette (Benowitz et al., 2006; et al., 1990; Butschky et al., 1995; Gross
et al., 1997; Hatsukami et al., 2013b; Higgins et al., 2017a; 2017b; Perkins et al., 1996;
2016; Shahan et al., 1999). Common dose-dependent negative subjective effects include
Aversion, Harshness, Increased Heartbeat, Jitteriness, and Light Headedness/Dizziness
(Benowitz et al., 2006; Higgins et al., 2017a; Perkins et al., 1996; 2016). While both
positive and negative subjective effects have been reported, positive effects are more
frequently documented.
1.3.2.1.2. Subjective effect measures that predict SA of cigarettes varying in
nicotine content. To our knowledge, there are two studies which assess how subjective
effects correspond to SA and choice of cigarettes which vary in nicotine content.
One of the two studies which analyzed the relationship between cigarette SA
preference and subjective effects was very recently published and included a VLNC (0.4
mg/g) and a normal nicotine content cigarette (15-17 mg/g) (Perkins, Karelitz & Kunkle,
2018). This study showed that subjective effect items Liking, Satisfying and How Much
Flavor, significantly predicted preference for the normal nicotine content cigarette when
concurrently available with a VLNC. Subjective effect items How Much Nicotine and
Strong did not significantly predict choice.
The second study directly evaluating how well subjective effect data corresponds
to SA of cigarettes which vary in nicotine content was conducted by our group (Arger et
10

al., 2017). This study will be described in more detail as it sets the stage for the current
study. Arger et al. included 26 participants in a pilot study for a larger laboratory study
evaluating the acute effects of cigarettes which varied in nicotine content (0.4 mg/g, 2.4
mg/g, 5.2 mg/g and 15.8 mg/g). Based on the definitions provided earlier, the 0.4 dose
cigarette is considered a VLNC cigarette, the two intermediate doses are considered RNC
cigarettes and the 15.8 cigarette is a normal nicotine content cigarette which
approximates the dose found in commercially available cigarettes. Participants came
from one of three vulnerable populations, namely socioeconomically disadvantaged
women of childbearing age, opioid-maintained individuals and individuals with affective
disorders, as smoking is overrepresented among and disproportionately affects these atrisk groups (Hser, Hoffman, Grella & Anglin, 2001; Lasser, Boyd, Woolhandler,
Himmelstein, McCormick & Bor, 2000; Schroeder, 2016).
This study evaluated how well subjective ratings on the modified Cigarette
Evaluation Questionnaire (mCEQ) measured during initial cigarette sampling sessions
predicted the relative reinforcing effects of cigarettes evaluated later in the study during
concurrent choice SA. The mCEQ consists of 12 questions and is designed to query the
degree to which a participant experiences the reinforcing effects of smoking. The
questionnaire was initially developed and used to evaluate the efficacy of
pharmacotherapies which were thought to influence the reinforcing effects of cigarette
smoking (mecamylamine, nicotine replacement, varenicline; Cappelleri et al. 2007; Rose
et al., 1994; Westman et al., 1992). Research from our group suggests that the mCEQ is
sensitive to dose differences (Higgins et al., 2017a, 2017b). However, it does not appear
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to function differently among individuals with varying levels of nicotine dependence
(Cappelleri et al., 2007, Higgins et al., 2018).
The twelve questions of the mCEQ generate five subscales, namely (1)
Satisfaction, (2) Psychological Reward, (3) Enjoyment of Respiratory Tract Sensations,
(4) Craving Reduction and (5) Aversion, each made up of 1-5 items (Table 1-1).

Participants indicated how true a statement was using a Likert scale which ranged from 1
(Not at all) to 7 (Extremely). To evaluate different dose comparisons, subjective effect
difference scores for each of the five subscales were computed by subtracting the lower
dose cigarette subjective effect score from the higher dose cigarette subjective effect
score, with positive scores indicating the higher dose cigarette produced greater intensity
of a subjective effect and negative scores indicating the lower dose cigarette produced
greater intensity of a subjective effect. For example, a participant with a Satisfaction
score of 5 for the 15.8 mg/g dose and 2 for the 0.4 mg/g dose would have a Satisfaction
difference score of 3. Difference scores can range from -6 to +6. Preference for the
higher dose in the SA task was computed by dividing the number of times the higher dose
was chosen by the total number of choices made and then multiplied by 100 to derive a
12

percentage. Higher percentages indicated a greater preference for the higher dose. For
example, a participant who earned 8 puffs of the 15.8 dose cigarette and 2 puffs of the 0.4
mg/g dose cigarette while the two doses were concurrently available chose the higher
dose 80% of the time. Three dose comparisons (i.e., 15.8 mg/g v. 5.2 mg/g, 15.8 mg/g v.
2.4 mg/g, 15.8 mg/g v. 0.4 mg/g) were included in the analyses. Dose comparisons not
including the 15.8
mg/g cigarette were
not examined in
this study due to
power concerns.
In this
preliminary report,
higher Satisfaction
difference scores
and lower Aversion
difference scores
predicted a

Figure 1-2. Satisfaction and Aversion subscale difference scores predicting
preference for the 15.8 mg/g in three dose comparisons. These two mCEQ
subscales were equally predictive of choice regardless of dose comparison.
β represents the fixed effect estimate of the strength of the association
between the subscale difference scores and % choice for 15.8 mg/g cigarette
collapsed across dose. This figure is adapted from “Preliminary validity of
the modified Cigarette Evaluation Questionnaire in predicting the
reinforcing effects of cigarettes that vary in nicotine content” by Arger, C.
A., et al., 2017, Experimental Clinical Psychopharmacology, 25(6), 473478.

preference for the
higher dose cigarette when available concurrently with reduced nicotine content
cigarettes (Figure 1-2). Psychological Reward, Enjoyment of Respiratory Tract
Sensations and Craving Reduction effects do not appear to be predictive of concurrent
choice performance.
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Across the two studies that have assessed how behavioral assessments correspond
to subjective effects of cigarettes which vary in nicotine content, Satisfaction appears to
be an important subjective effect in predicting SA preference. Negative subjective effects
(i.e., Aversion) may independently predict preference as well, as documented in one of
the two studies (Arger et al., 2017).
While a contribution to the literature, the study conducted by Arger and
colleagues did not have a large enough sample size to evaluate how well subjective
effects predict choice in intermediate dose comparisons (e.g., 0.4 mg/g v. 2.4 mg/g).
Therefore, it is unclear how sensitive the mCEQ is for assessing dose comparisons which
are closer in magnitude and do not approximate nicotine content found in commercially
available cigarettes. In addition, because of the small sample size with small subsets of
each vulnerable population (socioeconomically disadvantaged women, n = 9; opioidmaintained patients, n = 11, individuals with affective disorders, n = 6), the preliminary
analyses could not determine if the mCEQ subscale scores are equally predictive of
choice across different smoker populations.
1.3.2.2. Hypothetical purchasing tasks. Purchase tasks are another self-report
method for assessing the abuse liability of cigarettes that were developed more recently.
Purchase tasks assess the demand of a given reinforcer across a range of hypothetical
monetary costs. This measure incorporates concepts from the field of behavioral
economics which applies microeconomic theories of demand and supply to understanding
the maintenance of behavior by their reinforcers. Purchase tasks can be easily and
quickly administered after a single exposure to a drug.
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Typically, hypothetical purchase tasks query the number of units of a given
commodity (e.g., cigarettes) a participant would want in a 24-hour period at escalating
price points. Purchase tasks produce a demand curve which typically shows that
consumption of a commodity decreases as the price increases. Using a purchase task,
drug demand is also characterized by the relationship between total expenditure as a
function of price per
drug unit, captured

Q0

with an inverted Ushaped curve. From
these two curves, five
indices can be
computed which
characterize drug
consumption
underprice constraints:
(1) Intensity (Q0), (2)
Price per drug unit
when consumption
becomes elastic (Pmax),
(3) Breakpoint (4)
Maximum Expenditure
(Omax) and Elasticity

Figure 1-3. Prototypic demand curve (panel A) and expenditure
curve (panel B) from which the five indices of the purchase task
are derived. Adapted from “Bidwell L. C., MacKillop, J.,
Murphy, J. G., Tidey, J. W., Colby, S. M. (2012). Latent factor
structure of a behavioral economic cigarette demand curve in
adolescent smokers. Addictive Behaviors, 37, 1257-1263.”

(α). Intensity (Q0)
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captures drug consumption when there are no costs (i.e., free) and represents
unconstrained consumption of the reinforcer (Figure 1 – 3, Panel A). Pmax is the price per
drug unit when the participant incurs the most costs and represents the point at which the
demand curve becomes elastic, or sensitive to price (Figure 1 – 3, Panel A and B).
Breakpoint is the price point at which participants will no longer purchase any cigarettes
because costs are too high (Figure 1 – 3, Panel A). Omax is the largest amount of money
expended in the hypothetical purchase task at a single price point and represents the
largest cost a participant is willing to incur to obtain a drug (Figure 1 – 3, Panel B).
Elasticity (α) is an index calculated from the other values that captures the slope of the
demand curve and describes how consumption is sensitive to escalating prices (not a
single point on either figure). While these five indices are often highly correlated, they
represent unique facets of how the consumption of a reinforcer can be affected by
monetary constraints.
1.3.2.2.1. Hypothetical purchase tasks for cigarettes that vary in nicotine
content. The Cigarette Purchase Task (CPT) was developed and first tested by Jacobs
and Bickel (1999) to create a less-burdensome procedure for capturing the reinforcing
effects of a drug. Opioid-dependent individuals completed hypothetical purchase tasks
for cigarettes and heroin and the data from those hypothetical purchase tasks were well
described by a demand curve typically used to summarize SA data. Indeed, patterns of
consumption followed a typical demand pattern where consumption decreased as prices
increased. While this and other early purchase task studies used hypothetical scenarios,
subsequent studies have confirmed that the results produced by CPT are highly correlated
with real and potentially real laboratory cigarette purchasing data (Wilson et al., 2016).
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Like SA procedures, CPT indices are also sensitive to environmental factors which
typically influence reinforcers (e.g., deprivation, dose, presence of drug cues; Dahne,
Murphy & MacPherson, 2016; Higgins et al., 2017b; MacKillop et al., 2012). These
studies provide converging evidence that acute reinforcing effects are captured with this
self-report method. While the CPT was originally designed to be a less burdensome
complement to SA, its utility appears to extend beyond acute relative reinforcing effects
as assessed by SA. Because the CPT takes into consideration the effect of environmental
constraints on the consumption of cigarettes, it appears to isolate additional factors which
can influence severity of cigarette use. This is evidenced by the ability of the CPT to
detect individual differences like (1) cigarettes smoked per day (Dahne et al., 2016;
Higgins et al., 2017b; MacKillop et al., 2008; Murphy, MacKillop, Tidey, Brazil &
Colby, 2011; O’Connor et al., 2014; Secades-Villa, Pericot-Valverde & Weidberg, 2016),
(2) nicotine dependence scores (Bidwell et al., 2012; Farris et al., 2017; Higgins et al.,
2018; MacKillop et al., 2008; Murphy et al., 2011; O’Connor et al., 2014; Peters et al.,
2017; Secades Villa et al., 2016; Secades Villa et al., 2017), (3) history of quit attempts
(Bidwell et al., 2012; Higgins et al., 2017), (4) intensity of craving scores (O’Connor et
al., 2014; MacKillop, Brown, Stojek, Murphy, Sweet & Niaura, 2012), (4) the presence
or absence of additional substance use (Farris et al., 2017; Parker et al., 2018) and (5)
presence or absence of psychopathology (Dahne et al., 2016; Farris et al., 2017;
MacKillop & Tidey, 2011; Secades Villa et al., 2016, 2017). These results suggest that
the CPT is a relevant tool for assessing abuse liability and clinically meaningful
individual differences related to abuse liability.
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Likely because it was developed more recently, the CPT has been used
infrequently to characterize the abuse liability of cigarettes with varying nicotine content.
For example, in the large randomized trial by Donny and colleagues (2015) that evaluated
cigarettes with varying levels of nicotine and was described earlier, participants who
were assigned to smoke the lowest dose cigarette (0.4 mg/g) reported that after 6 weeks
of use, their assigned cigarette had significantly lower Intensity (Q0), Maximum
Expenditure (Omax) and Breakpoint and higher Elasticity (α) compared to cigarettes with
higher doses of nicotine (Smith et al., 2016). In addition, the recent laboratory study by
our group assessing cigarettes with varying levels of nicotine among vulnerable
populations also captured differences in cigarette purchase task indices after a single
exposure to the cigarettes. Specifically, very low nicotine content cigarettes had
significantly lower Intensity (Q0), Price at point of Elasticity (Pmax), Breakpoint and
Maximum Expenditure (Omax) compared to cigarettes with higher doses of nicotine
(Higgins et al., 2017).
1.3.2.2.2. Purchase task indices which predict SA. While the existent literature
on the CPT consistently captures a range of individual differences, there is only one study
which directly tested the relationship between purchase tasks and SA data. In a study
involving normal nicotine content cigarettes and other tobacco products, Breakpoint for
cigarettes derived from SA under a progressive ratio schedule of reinforcement did not
consistently correspond with the number of cigarettes subsequently purchased in a
laboratory purchasing task (Stein et al., 2017). Specifically, Breakpoint derived from SA
under a progressive ratio schedule of reinforcement positively and significantly
corresponded to laboratory purchases of cigarettes at the lowest price (12¢ each), but not
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at higher prices (25¢, 50¢ or $1 each). These results were somewhat surprising but could
possibly be an artifact of the study design, which assessed cigarettes and other tobacco
products in isolation with SA but pairs of tobacco products in the laboratory purchasing
tasks. Further, this study was limited because of its inability to describe the relationship
between specific indices of the CPT and SA because in many cases the indices were
inestimable with participant-level data.
The CPT may offer unique information about the abuse liability of cigarettes and
could inform regulatory efforts to address the addictiveness of cigarette smoking (Tidey
et al., 2016). The single study where the relationship between CPT and SA was assessed
was limited to normal nicotine content cigarettes and involved general population
smokers. It remains to be seen how indices derived from the CPT correspond to data
collected from SA paradigms.
1.4 Aims
Our research group recently completed the laboratory-based study which was
piloted in the sample evaluated by Arger and colleagues (Higgins et al., 2017b). The
completed study included data from 169 individuals who completed all phases of the
study. This sample size allowed us to extend the work of Arger et al. (2017) by assessing
all six dose comparisons and determining the generalizability of the predictive validity of
the mCEQ in various smoker populations. In addition, the CPT was collected which
allowed us to exam the correspondence of CPT indices with choice preference assessed
in a concurrent choice SA paradigm.
Based on previous research with the mCEQ, it was hypothesized that Satisfaction
and Aversion would predict choice. Because previous studies on the topic were limited
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by sample size or did not include vulnerable populations, no specific hypotheses were
made regarding predictive utility as a function of dose comparison or vulnerable
population.
With regards to the CPT, it was unclear what index or indices might best
correspond to preference given the relative dearth of studies on the topic. Theoretically,
one might hypothesize that relative Intensity (Q0) for two cigarettes (i.e., the difference in
the number of cigarettes of each dose a smoker would smoke if both cigarettes were free)
would be most likely to correspond to preference for cigarettes available under an equal
response cost. As there are no data to our knowledge to suggest that the relationship
between Intensity and choice would vary across dose comparison nor vulnerable
population, no specific hypotheses were made regarding potential interactions of
Intensity with dose or vulnerable population.

20

CHAPTER 2: METHOD
The parent study for this secondary analysis is a large, multisite, 14-visit
laboratory-based study evaluating the acute effects of cigarettes with varying levels of
nicotine under double blind conditions among three vulnerable populations
(socioeconomically disadvantaged women of childbearing age, opioid-maintained
individuals and individuals with affective disorders, Higgins et al., 2017b). Data were
collected using the same protocol utilized by Arger and colleagues (2017) that was
briefly described in the Introduction. Procedures relevant to the present analyses are
described in more detail below.
2.1. Participants
We used data collected from 169 smokers (53 socioeconomically disadvantaged
women, 60 opioid-maintained men and women and 56 men and women with affective
disorders) who completed all 14 sessions of the study. Participants were recruited via ads
on Facebook, Craigslist, and in local newspapers, as well as flyers posted on community
bulletin boards. The study took place at three sites: the University of Vermont in
Burlington, VT: Johns Hopkins University in Baltimore, MD; and Brown University in
Providence, RI. All potential participants attended a two-hour screening session. After
providing informed consent, potential participants submitted breath samples (Micro+
Smokerlyzer; coVita/Bedfont, Haddonfield, NJ) and urine samples (NicAlert cotinine test
strip; Nymox, Hasbrouck Heights, NJ) to determine smoking status; urine samples were
also tested for pregnancy status. Next, potential participants completed demographic
(e.g., age, race/ethnicity, education, marital status, etc.) and medical history
questionnaires developed in our laboratory, and then completed a series of standardized
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questionnaires about their tobacco use, including the Fagerstrom Test for Nicotine
Dependence, (FTND, Heatherton, Kozlowski, Frecker & Fagerstrom 1991; Pomerleau,
Majchrzak, & Pomerleau, 1989; Pomerleau, Carlton, Lutzke, Flessland & Pomerleau,
1994), and their mental health history, including the Mini International Neuropsychiatric
Interview (MINI) 6.0 (Sheehan et al., 1998) and the Beck Depression Inventory (Beck,
Ward & Mendelson, 1961).
To be eligible, participants self-reported using at least 5 cigarettes per day for the
past year and had an intake breath carbon monoxide (CO) sample > 8 ppm. Individuals
were excluded if they reported exclusively rolling their own cigarettes, using other
tobacco or nicotine products 9 or more days in the last 30 days, or any smoking cessation
product use in the last 30 days. All participants were without current serious mental
disorders, lifetime psychosis or dementia, substance abuse, and suicidal ideation. In
addition to the above-mentioned inclusion criteria, the three vulnerable populations of
interest had additional population-specific inclusion criteria. Socioeconomically
disadvantaged women were between the ages of 18 and 44 and their highest level of
educational achievement was a high school degree. Opioid-maintained individuals were
between the ages of 18 and 70 and their prescribing physician confirmed they had >70%
drug-free urines in the past month. Finally, participants with affective disorders were
between the ages of 18 and 70 and met criteria on the MINI for major depression
disorder, general anxiety disorder, post-traumatic stress disorder, obsessive compulsive
disorder, phobia or panic disorder.

22

2.2. Materials
2.2.1. Research cigarettes. Spectrum nonmenthol and menthol research
cigarettes were manufactured by 22nd Century (Clarence, NY) in conjunction with the
National Institute of Drug Abuse. The doses used in the current protocol were 0.4, 2.4, 5.2
and 15.8 mg/g.
2.2.2. CReSS desktop smoking topography device
To implement controlled
puffing procedures that would be
used in later phases of the study,
participants smoked all research
cigarettes through the CReSS
Desktop Smoking Topography
Device (Borgwaldt, Richmond,
Virginia). The smoking topography
device is an 8” X 6” X 5” console
with two tubes connected to the
front (Figure 2-1, Panel A). The
tubes extend about three feet and
connect to a mouthpiece which
holds a cigarette (Figure 2-1, Panel
B). Individuals smoke the cigarette through the mouthpiece. The device can measure
several parameters of puffing behavior including length, size and velocity. All data are
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transferred from the console to a desktop PC via a USB cable. Puff volume is displayed
on a computer screen in real time. Researchers can also display target puff volumes and
timers to guide participants to puff in specific patterns. The CReSS Smoking
Topography Device has been shown to have good reliability and validity (Blank,
Disharoon & Eissenberg, 2008; Lee, Malson, Waters, Moolchan, & Pickworth, 2003).
2.2.3. Modified Cigarette Evaluation Questionnaire (mCEQ). As described
previously, the mCEQ captures subjective effects of cigarette smoking. Participants rate
each of the 12 questions (Table 1-1) on a Likert scale which ranges from 1 (not at all) to 7
(extremely). The answers are combined to form five unique subscales which quantify (1)
Satisfaction, (2) Psychological Reward, (3) Enjoyment of Respiratory Tract Sensations, (4)
Craving and (5) Aversion. The mCEQ was originally designed to measure changes in the
reinforcing effects of smoking following a pharmacological intervention (Brauer et al.,
2001, Rose et al., 1994, Rose et al., 1998, Westman et al., 1992). The most recent version
was developed and validated according to data collected from three clinical trials testing
the effects of varenicline for smoking cessation (total N = 1,565; Cappelleri et al., 2007).
The subscales which make up the questionnaire used in this study demonstrate satisfactory
convergent validity and have demonstrated good test-retest reliability.
2.2.4. Cigarette Purchase Task (CPT). As described in the introduction, the
CPT queries how many cigarettes a participant would purchase at various given prices.
The instructions when participants completed the CPT are as follows:
Think about HOW YOU ARE FEELING RIGHT NOW. The following
questions how many cigarettes you would smoke if they cost various amounts of
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money. ASSUME THAT: (1) The available cigarettes are your assigned study
cigarettes. (2) You have the same income/savings that you have now and NO
ACCESS to any cigarettes or nicotine products other than those offered at these
prices. (3) You can smoke without any restrictions and without factoring in what
might occur in the next 24 hours related to your participation in the study. (4) You
would smoke the cigarettes that you request at this time, not save or stockpile
cigarettes for a later date. Be sure to consider each price increment carefully.
Participants then provided responses for how many cigarettes they would
purchase at 20 different price points per cigarette (free, 2¢, 5¢, 10¢, 20¢, 30¢, 40¢, 50¢,
60¢, 70¢, 80¢, 90¢, $1, $2, $3, $4, $5, $10, $20, $40). Each price point was shown as
price per cigarette and price per pack (e.g., $1 per cigarette OR $20 per pack). After
completing the CPT, research assistants reviewed the data to assess any unsystematic
data (e.g., increasing consumption across increasing prices, decreases in consumption as
price points increased followed by increases in consumption at higher price points). If
the data followed unsystematic patterns, research assistants re-explained the task and
gave the participant an opportunity to change their data.
2.2.4.1. Computing CPT indices. Four of the five indices of the CPT (Intensity
(Q0), Pmax, Breakpoint, Omax,) were empirically quantified from observed values. As
discussed in the Introduction, Intensity is the quantity of cigarettes ‘purchased’ when they
were free, Omax is the largest sum incurred in a single price condition when hypothetically
purchasing cigarettes, Pmax is the price point at which Omax occurs and represents the
point at which participants become sensitive to price and Breakpoint is the point at which
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a participant first reports they would purchase zero cigarettes, presumably because the
costs are too high.
To generate Elasticity, participant-level data were fit to a demand curve (lnQ =
lnQ0 k(e-α(Q0C) – 1)) where Q is the quantity consumed, Q0 is the quantity consumed when
the cigarette is free (y-intercept), k is the range of the cigarettes consumed in logarithmic
units and was kept constant across all individual curve fits and C equals the unit price.
To log transform the data and model the demand curve, price points where participants
reported smoking zero cigarettes were replaced with .001. α represents individual
differences in the rate of change in consumption with changes in price (i.e., Elasticity;
Hursh & Silberberg, 2008) and was derived for each participant from the demand curve
based upon their responses.
2.3 Procedures
If deemed eligible at the screening visit, participants were invited to participate in
the study. Participants completed each of the 14 visits under acute abstinence which was
biochemically verified with at least a 50% reduction in their screening CO value; this is
an abstinence criterion widely used in tobacco research (e.g., Johnson, Bickel &
Kirshenbaum, 2004; Tidey, O’Neill & Higgins, 1999). The study was divided into a
baseline visit and three phases (Phases 1 – Phase 3). All laboratory sessions took place in
a small room (30 ft2) with a ventilation system specifically designed to allow for cigarette
smoking indoors. The rooms had two computers, a laptop and a desktop computer,
which were used to (1) complete questionnaires and complete the concurrent choice
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program and (2) measure smoking behavior, respectively. The analyses proposed will
use data from Phases 1 and 2, which are described in more detail below.
Phase 1 consisted of four visits where participants sampled a single research
cigarette on distinct days and provided subjective effect ratings and CPT responses.
After biochemical confirmation of acute abstinence, participants took 2 ad lib puffs on
their usual brand cigarette. This was done to equate the time since last puff across all
participants. After a 30-minute period, participants smoked the assigned research
cigarette ad lib through the desktop smoking topography device. Each cigarette was
labelled with an arbitrary letter code (e.g., A, B, C and D) which differed depending on
the sequence to which each participant was randomized. While smoking the cigarette,
participants were encouraged to take detailed notes on their smoking experience, which
were saved for Phase 2. Immediately after smoking the cigarette, participants completed
the mCEQ and CPT. In the hour that followed, participants completed other
questionnaires and provided CO samples at fifteen-minute intervals; those data have been
reported elsewhere (Higgins et al., 2017b). At the end of the hour, participants practiced
controlled puffing procedures with specific puffing size and length requirements with the
same dose research cigarette.
Phase 2 consisted of six visits where participants chose between two cigarettes,
Table 2-1. Nicotine Dose Comparisons

both available on a fixed-ratio schedule of
reinforcement (FR-10). Each dose comparison was
tested once in separate sessions (Table 2-1).
Participants were randomized to a dose comparison
presentation sequence. As in Phase 1, researchers
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15.8 mg/g

0.4 mg/g

15.8 mg/g

2.4 mg/g

15.8 mg/g

5.2 mg/g

5.2 mg/g

0.4 mg/g

5.2 mg/g

2.4 mg/g

2.4 mg/g

0.4 mg/g

biochemically confirmed acute abstinence at the beginning of each Phase 2 session and
participants took two puffs on their usual brand cigarette and waited 30 minutes before
beginning session procedures. Two different dose cigarettes labelled with the letter codes
used in Phase 1 were available to smoke. Researchers provided participants with a copy
of their notes from Phase 1. When participants wanted to smoke a certain cigarette, they
clicked 10 times on an icon on the laptop computer which had the letter code of the
corresponding cigarette (Figure 2-2). Participants then lit the selected cigarette without
inhaling, placed it in the mouth piece of the desktop smoking topography device and took
two controlled puffs exactly as they practiced in Phase 1 and with feedback displayed on
the desktop monitor.
Participants were
given 2 minutes to
take the two puffs.
During each 3-hour
session in Phase 2,
participants could
make as many or as
few choices for
either cigarette as
they wanted.
2.4 Statistics
All statistical data preparation and analyses were conducted using Statistical
Analysis Software (SAS) version 9.4. Significance testing was determined at p < .05.
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2.4.1. Preparing Data for Analysis.
2.4.1.1. Predictor variables. As previously described, difference scores were
calculated for each mCEQ subscale by subtracting scores for the lower dose from scores
of the higher dose for each of the six dose comparisons. Difference scores can range
from - 6 to + 6 and more positive difference scores indicated greater subjective effects at
the higher dose.
For CPT data, Elasticity values greater than 1.00 were winsorized to 1.00 prior to
statistical analysis (22 of 845 cases). All other demand indices were empirically
quantified from observed values. We reviewed CPT results and found systematic
patterns in 92.7% of demand curves; no data were excluded from analyses. In cases
where participants reported zero consumption across all prices (54 of 845 cases), curve
fitting was not possible, so Elasticity was not analyzed, and other demand indices were
quantified as 0. Demand curves for the four doses of cigarettes had R2s which ranged
from 0.97 - 0.98, indicating that the demand curves sufficiently described the pattern of
the data collected.
Once all indices were empirically quantified, difference scores were calculated for
each of the five CPT indices using the same approach used for each mCEQ subscale.
Ranges depended on the index being computed.
2.4.1.2. Outcome variables. To quantify relative reinforcing effects of the cigarettes
using data from the concurrent choice assessment, a ratio was calculated for each of the
six dose comparisons. Each ratio was computed by dividing the total puffs earned for the
higher of the two doses available by the total puffs earned in the choice session. Ratios
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were multiplied by 100 to produce a percentage, with higher percentages indicating more
choices for the higher dose cigarette.
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑓𝑓𝑠 𝐸𝑎𝑟𝑛𝑒𝑑 𝑓𝑜𝑟 𝐻𝑖𝑔ℎ𝑒𝑟 𝐷𝑜𝑠𝑒
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑓𝑓𝑠 𝐸𝑎𝑟𝑛𝑒𝑑

X

100

2.4.2. Assessing the Predictive Utility of Individual Subscales and Indices. The
aims of the statistical analyses were to assess how well mCEQ subjective effect
difference scores and CPT index differences scores predict preference for the higher dose
in a given dose pair. Mixed effects repeated measures analysis of variance tests were
used to predict proportion of choices for the higher dose with dose comparison as the
repeated fixed effect and mCEQ and CPT difference scores, the main independent
variables of interest, as a fixed effect. This allowed us to evaluate whether subjective
effects and CPT indices were predictive of choice at all dose comparisons.
There were five variables which were included in the statistical analyses for the
primary aim to account for any variability introduced by the design of the parent study.
They remained in the model regardless of whether they were predictive of choice. The
model included a fixed effect for session and a random effect for the sequence of dose
comparison presentations since participants were randomized to receive all dose
comparisons within a Latin square design. Vulnerable population group was entered as
an additional fixed effect as the study included three vulnerable population groups which
varied in how they were recruited and their inclusion criteria. Site (i.e., University of
Vermont, Johns Hopkins University and Brown University) was also included in the
model as a random effect. Finally, because participants could take as many or as few
puffs as that they wanted in the choice session, total puffs earned were entered as an
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additional fixed effect in all models testing the predictive utility of the mCEQ and CPT
for predicting choice.
Interaction terms were included in the model to evaluate how well mCEQ or CPT
difference scores predicted choice and whether this depends on dose comparison or
vulnerable population group. If any interaction terms were not significantly predictive of
choice, the term was eliminated, and the model was re-run without the nonsignificant
interaction term. This process was repeated until the model contained only main effects
or main effects and significant interaction terms.
2.4.3. Assessing Independent Predictors of Choice. After each subscale was
evaluated independently, two separate models evaluated which mCEQ subscales were
independent predictors of choice and which CPT indices were independent predictors of
choice. This first model included all of the subscale difference scores as a fixed effect.
Non-significant subscales with the highest p-value were removed from the model and the
model was rerun until the only subscales which remained were significant predictors of
choice. This process was repeated for a second model evaluating which CPT indices
were significant, independent predictors of choice.
In a final model, all five mCEQ subscales and all five CPT indices were entered as
predictors of choice. Again, predictors with the largest p-values were removed from the
model and the model was rerun until only significant subscales or indices remained in the
model.
2.4.4. Power Analysis. Using data from the pilot study (Higgins et al., 2017a),
similar analyses using a sample of 26 individuals resulted in a statistically significant
effect of differences in Satisfaction and Aversion on the choice of cigarettes with an eta31

squared of 0.08 and 0.05, respectively (Arger et al., 2017). Our sample size of 169 is
sufficient to detect a similar effect size with 90% power including all 6 dose
comparisons.
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CHAPTER 3: RESULTS
3.1. Participant Characteristics
As

Table 3-1. Participant Characteristics

reported in
Higgins et al.

All
(n=169)
35.6 ±
11.4
71

Age (mean yrs + SD)
Gender (% Female)

(2017b), the
majority of the
169 participants
were female,
Caucasian, had a
high school

Disadvantaged
Women
(n=53)

Opioid
Abusers
(n=60)

Affective
Disorders
(n=56)

30.0 ± 7.0

41.0 ± 11.2

35.0 ± 12.4

100

60

55

Race (%)
White

73

77

70

71

American Indian/Alaskan Native

0

0

0

0

Asian

0.6

0

0

2

Black/African-American

14

15

20

5

Native Hawaiian/Pacific Islander

0.6

0

2

0

Other/more than 1 race

9

4

9

14

Latino

3

4

0

6
2

Education (%)
8th Grade or Less

2

2

3

Some High School

14

17

17

7

High School Graduate/Equivalent

34

38

37

28

Some college

38

43

35

36

2-Year Associate’s Degree

6

0

8

9

College Graduate/4-Year Degree

3

0

0

11

Graduate or Professional Degree

2

0

0

7

Married

15

27

7

14

Never Married

61

64

53

66

Divorced/Separated

21

8

35

17

Widowed

2

2
14.5 ± 6.3

3
16.5 ± 6.1

2
16.3 ± 9.5

Marital Status (%)

education or less
and were never

Cigarettes per Day (M + SD)

married (Table 3-

15.8 ± 7.5

Primary Menthol Smoker (%)

35

Age Started Smoking Regularly (mean yrs + SD)

16.3 ± 4.3

30
16.4 ± 3.7

38
16.2 ± 5.5

36
16.2 ± 3.1

Fagerstrm Test for Nicotine Dependence (M + SD)

5.0 ± 2.2

4.6 ± 2.3

5.3 ± 1.8

5.0 ± 2.3

1).
On average, participants smoked 16 cigarettes per day and 35% of participants
were primary menthol cigarette smokers. Participants started smoking regularly at 16
years old and had moderate levels of dependence according to the Fagerstrӧm Test for
Nicotine Dependence. These factors did not significantly differ by group, therefore we
did not control for them statistically.
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3.2. Descriptive Statistics for Predictor and Outcome Variables
Table 3-2. Mean (SE) mCEQ Subscale Difference Scores by Dose Comparison
Dose Comparison
Subscale

0.4 vs. 2.4

2.4 vs. 5.2

0.4 vs. 5.2

5.2 vs. 15.8

2.4 vs. 15.8

0.4 vs. 15.8

Satisfaction
Psychological
Reward
Enjoyment of
Respiratory
Tract
Sensations
Craving
Reduction

0.41 (0.14)

0.26 (0.13)

0.67 (0.13)

0.77 (0.14)

1.03 (0.14)

1.45 (0.14)

0.16 (0.10)

0.23 (0.10)

0.39 (0.11)

0.37 (0.11)

0.60 (0.11)

0.76 (0.11)

0.22 (0.14)

0.42 (0.13)

0.64 (0.14)

0.58 (0.14)

1.00 (0.16)

1.22 (0.16)

0.30 (0.16)

0.29 (0.15)

0.59 (0.15)

0.57 (0.15)

0.96 (0.15)

1.15 (0.17)

Aversion

0.04 (0.05) 0.01 (0.06) 0.04 (0.06) 0.24 (0.07)

Table 3-3. Mean (SE) CPT Index Difference Scores by Dose Comparison
Dose Comparison
CPT
0.4 vs. 2.4
2.4 vs. 5.2
0.4 vs. 5.2
5.2 vs. 15.8
Index
Elasticity
-0.06 (0.02) -.02 (0.01)
-0.21 (0.01) -0.02 (0.01)
Intensity
0.40 (0.82)
1.59 (0.61)
2.03 (0.69)
0.44 (0.66)
Omax
-4.61 (6.41) 3.93 (4.30)
-0.44 (3.49) 8.79 (4.71)
Pmax
0.10 (0.57)
0.42 (0.52)
0.52 (0.63)
0.72 (0.68)
Breakpoint 0.36 (0.92)
0.55 (0.98)
0.91 (0.93)
1.07 (1.00)

0.24 (0.08) 0.28 (0.07)

2.4 vs. 15.8

0.4 vs. 15.8

-0.04 (0.02)
2.05 (0.76)
12.53 (7.83)
1.14 (0.67)
1.63 (0.75)

-0.04 (0.02)
2.52 (0.88)
8.51 (4.74)
1.25 (0.58)
2.32 (0.87)

mCEQ subscale and CPT index difference score means and standard errors are
presented for each dose comparison in Tables 3-2 and 3-3. As reported in Higgins et al.
(2017b), participants showed dose-dependent increases in all five mCEQ subscales and
four of the five CPT indices (Intensity, Pmax, Breakpoint, Omax). Means and standard
errors for the proportion of choices for the higher dose cigarette in the six dose pairs are
summarized in Table 3-4. As reported in Higgins et al. (2017b), participants showed
significantly greater preference for the higher dose in a given dose pair with greater
Table 3-4. Mean (SE) Proportion of Choice for Higher Dose in a Give Dose Pair
Dose Comparison
0.4 vs. 2.4
2.4 vs. 5.2
0.4 vs. 5.2
5.2 vs. 15.8
2.4 vs. 15.8
Proportion
of Choice
.58 (.03)
.57 (.03)
.62 (.03)
.64 (.03)
.68 (.03)
for Higher
Dose

preference shown when the dose contrast was larger.
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0.4 vs. 15.8
.71 (.03)

3.3. mCEQ Subscales as Predictors of Choice
When analyzed separately, all five mCEQ subscales were predictive of choice.

C

A
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D
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Figure 3-1. mCEQ subscale difference scores and cigarette preference across six dose comparisons
(gray lines) and collapsed across dose comparisons (black lines). mCEQ subscales did not predict
choice differently across the dose comparisons (Subscale X Dose Comparison, p’s > .05).

3.3.1. Satisfaction. Satisfaction was significantly predictive of choice regardless
of dose comparison, β = .07, F(1, 999) = 211.16, p < .0001 (Figure 3-1, Panel A).
Specifically, greater differences in Satisfaction scores were associated with greater
preference for the higher dose cigarettes; for every 1-point increase in Satisfaction
subscale scores, preference for the higher dose cigarette increased by 7%.
The final model used to evaluate the predictive utility of Satisfaction for cigarette
preference included one interaction term which was statistically significant (Satisfaction
X Vulnerable Population), F(2, 998) = 10.06, p < .001 (Figure 3-2). Across all
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populations, greater Satisfaction
difference scores corresponded to
greater preference for the higher dose
cigarette. However, socioeconomically
disadvantaged women appeared to show
greater increases in behavioral
preference as Satisfaction difference
scores increased. Specifically,
Figure 3-2. Satisfaction difference scores and
cigarette preference, collapsed across dose
comparisons and separated by project.

socioeconomically disadvantaged
women showed an 11% increase in

higher dose cigarette preference for every 1-point increase in Satisfaction difference
scores while individuals who were opioid-maintained and individuals with affective
disorders showed a 6% increase in higher dose cigarette preference for every 1-point
increase in Satisfaction. Post-hoc analyses controlling for sex, age and education did not
eliminate the significant interaction between satisfaction and vulnerable population for
predicting choice whereby changes in Satisfaction subscale difference scores
corresponded with larger increases in preference for the higher dose cigarette. Sex, age
and education were considered in post-hoc analyses because participants were
specifically recruited/enrolled based on these factors.
3.3.2. Psychological Reward. Psychological Reward was predictive of choice
regardless of dose comparison and vulnerable population, β = .07, F(1, 1003) = 95.01, p
< .0001 (Figure 3-1, Panel B). Specifically, greater differences in Psychological Reward
scores were associated with greater preference for the higher dose cigarettes; for every 1
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point increase in Psychological Reward, preference for the higher dose cigarette
increased by 7%. The final model used to evaluate the predictive utility of Psychological
Reward for cigarette preference did include any interaction terms.
3.3.3. Enjoyment of Respiratory Tract Sensations. Enjoyment of Respiratory
Tract Sensations was predictive of choice regardless of dose comparison and vulnerable
population, β = .06, F(1, 1004) = 141.17, p < .0001 (Figure 3-1, Panel C). Specifically,
greater differences in Enjoyment of Respiratory Tract Sensations were associated with
greater preference for the higher dose cigarettes; for every 1-point increase in Enjoyment
of Respiratory Tract Sensations, preference for the higher dose cigarette increased by 5%.
The final model used to evaluate the predictive utility of Enjoyment of Respiratory Tract
Sensations for cigarette preference did not include any interaction terms.
3.3.4. Craving Reduction. Craving Reduction was predictive of choice
regardless of dose comparison and vulnerable population, β = .03, F(1, 1002) = 45.35, p
< .0001 (Figure 3-1, Panel D). Specifically, greater differences in Craving Reduction
were associated with greater preference for the higher dose cigarettes; for every 1 point
increase in Craving Reduction, preference for the higher dose cigarette increased by 6%.
The final model used to evaluate the predictive utility of Craving Reduction for cigarette
preference did not include any interaction terms.
3.3.5. Aversion. Aversion was predictive of choice regardless of dose
comparison and vulnerable population, β = .03, F(1, 1003) = 4.66, p = .03 (Figure 3-1,
Panel E). Specifically, greater differences in Aversion were associated with greater
preference for the higher dose cigarettes; for every 1-point increase in Aversion,
preference for the higher dose cigarette increased by 3%. The final model used to
37

evaluate the predictive utility of Aversion for cigarette preference did not include any
interaction terms.
Because Aversion predicted choice in the opposite direction of previous findings
by Arger et al. (2017), post-hoc analyses examined how the two items comprising the
Aversion subscale (Nausea and Dizziness) predicted choice. Both Nausea and Dizziness
scores were significantly predictive of choice across dose comparisons and vulnerable
population. However, Nausea was significantly negatively predictive of choice, β = -.02,
F(1, 1003) = 4.23, p =.04, and Dizziness scores were significantly positively predictive of
choice, β = .04, F(1, 1003) = 22.61, p <.001.
3.3.6. mCEQ Subscales as Independent Predictors. When all five subscales
were included in a final model to test which subscales were independent predictors of
cigarette preference, only Satisfaction and Enjoyment of Respiratory Tract Sensations
remained significant, β = .06, F(1, 1001) = 52.32, p < .0001, β = .02, F(1, 1001) = 7.03, p
< .01, respectively. Higher Satisfaction and higher Enjoyment of Respiratory Tract
Sensations scores for the high dose cigarette corresponded to a higher proportion of
choices for the high dose cigarette. Specifically, for every 1-point increase in Satisfaction
or Enjoyment of Respiratory Tract Sensation difference scores, participants selected the
higher dose cigarette 6% and 2% more, respectively.
3.4. CPT Indices as Predictors of Choice
When analyzed separately, Intensity and Elasticity were predictive of choice and
Omax, Pmax and Breakpoint were not.

38

3.4.2. Intensity. Intensity was significantly and positively predictive of choice, β
= -.002, F(1, 944) = 19.44, p < .001. Specifically, higher Intensity corresponded to a
greater preference for the higher dose cigarette.
The final model used to assess the predictive utility of Intensity included a
significant Intensity X Dose Comparison X Vulnerable Population interaction. This
interaction revealed that Intensity is predictive in socioeconomically disadvantaged
women of childbearing
age (β = .02, F(1, 288)
= 18.35, p < .001) and
individuals with
affective disorders (β =
.004, F(1, 312) = 5.49,
p = .01), but not opioidmaintained individuals
(β = -.007, F(1, 336) =
0.00, p = .99; Figure 33). In addition, there
was a significant
Intensity X Dose
Comparison interaction
among the
socioeconomically
disadvantaged women of childbearing age, (F(5, 276) = 3.03, p = .01), where Intensity
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was only significantly predictive of choice in the 0.4 v. 2.4, 5.2 v. 15.8 and 2.4 v 15.8
dose comparisons.
3.4.1. Elasticity. Elasticity was significantly predictive of choice, β = -.22, F(1,
880) = 14.25, p < .001. Specifically, lower Elasticity difference scores were associated
with greater preference for the higher dose cigarettes; for every 0.1 point decrease in
Elasticity, preference for the higher dose cigarette increased by 2%.
The final model used to assess the predictive utility of Elasticity differed by
vulnerable population and dose comparison, Elasticity X Vulnerable Population X Dose
Comparison: F(2, 998) = 10.06, p < .001. In all three vulnerable populations of interest,
Elasticity was significantly, negatively associated with choice (Figure 3-4). However,
among opioid-maintained individuals, Elasticity was differentially predictive of choice
across different dose comparisons (Elasticity X Dose Comparison: F(5, 298) = 3.96, p =
.002), with Elasticity positively predictive of choice for the 2.4 v. 5.2 dose comparison
and negatively predictive for all other dose comparisons.
3.4.3. CPT Indices as Independent Predictors. When all five indices were
included in a model to test which were independent predictors of cigarette preference,
only Elasticity remained significant, β = -.21, F(1, 880) = 14.25, p < .001. Lower
Elasticity scores for the high dose cigarette corresponded to a higher proportion of
choices for the high dose cigarette.
3.5. Best Predictor of Choice
When all five mCEQ subscales and five CPT indices were included as predictor
variables in a final model, Satisfaction and Enjoyment of Respiratory Tract Sensations
were the only ones which remained predictive of choice preference for the higher dose
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cigarette, β = .06, F(1, 1001) = 53.32, p < .0001., β = .02, F(1, 1001) = 7.03, p < .001,
respectively.

Figure 3-4. Elasticity difference scores and cigarette choice preference across six
dose comparisons (gray lines) and collapsed across dose comparisons (black lines)
broken down by vulnerable population group. Among opioid-maintained individuals,
Elasticity predicted cigarette choice preference depending on the dose comparison
being analyzed.
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CHAPTER 4: DISCUSSION
In recent years, the FDA has taken steps to reduce the addictiveness of
combustible products. Relative reinforcing efficacy is a robust predictor of the addictive
properties of nicotine containing products. The present study tested the extent to which
the mCEQ and CPT, two self-report measures, captured acute relative reinforcing effects
of cigarettes which vary in nicotine content as measured by a behavioral measure,
concurrent choice SA.
4.1. mCEQ Predicting Choice
Even though not all mCEQ subscales were predictive of SA when tested in the
pilot sample, it is not surprising that all mCEQ subscales are significantly associated with
choice, as mCEQ subscales query moods and sensations that typically accompany
increases in nicotine dose (Benowitz et al., 2006; Boren et al., 1990; Butschky et al.,
1995; Gross et al., 1997; Hatsukami et al., 2013b; Higgins et al., 2017a; 2017b; Perkins et
al., 1996; 2016; Shahan et al., 1999). However, among all mCEQ subscales, Satisfaction
and Enjoyment of Respiratory Tract Sensations subscales were the only independent
predictors of choice. In addition, while Satisfaction was a significant predictor across
dose, the magnitude of prediction varied by population and was significantly greater
among women of childbearing age who are socioeconomically disadvantaged. Follow-up
analyses determined that statistically controlling for sex, age and education did not
eliminate the strength of Satisfaction in predicting choice among these populations. This
suggests that sex, age and education, which were constrained among socioeconomically
disadvantaged women of childbearing age due to specific inclusion criteria, did not drive
the strength of the relationship between Satisfaction and choice. While the predictive
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utility appears to vary in strength among certain groups, the overall pattern is consistent:
the greater a Satisfaction score is for a cigarette, the more likely it will be chosen. These
results paired with previous findings suggests that Satisfaction is the best subjective
effect for predicting relative reinforcing efficacy measured in a concurrent choice
paradigm (Arger et al., 2017; Perkins et al., 2018). Building on Arger et al. (2017), our
results also showed that the relationship between Satisfaction and choice was
significantly positively related at every dose comparison, including between reduced
nicotine content cigarettes.
The observation that Enjoyment of Respiratory Tract Sensations was an
independent predictor of choice was somewhat inconsistent with the results of Arger et al
(2017). Although the direction of the relationship was similar in both set of analyses, it
did not reach significance in Arger et al., perhaps due to issues around power and sample
size. Similar to Satisfaction, this subscale asks about the presence or absence of a
positively reinforcing subjective effect but unlike Satisfaction, this subscale is a cigarettespecific subjective effect. Participants sampled these cigarettes under acute abstinence,
which has been associated with increases in coughing and throat irritation, and laboratory
research demonstrates that nicotine suppresses coughing following extended abstinence
(Davenport, Vovk, Duke, Bolser & Robertson, 2009). Given that both sampling and
concurrent choice sessions were conducted under acute abstinence, it is possible that
coughing and respiratory discomfort was heightened prior to the session and that
cigarettes with higher nicotine doses better suppressed coughing and throat irritation and
thereby provided more favorable sensations and therefore were more preferable.
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According to our results, the subjective effects that best predict relative
reinforcing effects captured in concurrent choice SA paradigms are positive effects. This
finding is consistent with both previous studies which have tested this relationship (Arger
et al., 2017; Perkins et al., 2018). One the other hand, negative reinforcing effects, more
likely to be picked by items on the Craving Reduction and Psychological Reward
subscales, were no longer predictive of choice when positive reinforcing effects were
included in the model. Somewhat unexpectedly, Aversion was not independently
predictive of concurrent choice SA. Follow-up analyses determined that the two items
within the Aversion subscale (Nausea and Dizziness) predicted choice in opposite
directions, with Nausea negatively associated with preference for the higher dose and
Dizziness positively associated with preference for the higher dose. This discrepancy is
consistent with results from a confirmatory factor analysis of the mCEQ which found that
Aversion had less internal consistency than the other mCEQ subscales for capturing
subjective effects of reinforcement (Cappelleri et al., 2007). Our discrepant findings on
Aversion and choice may speak to the lack of consistency of the subscale. With regards
to cigarettes varying in nicotine content, it appears that these two factors (Nausea and
Aversion) should be considered separately as they function differently in terms of how
they relate to actual drug taking in concurrent choice SA paradigms.
4.2. CPT Predicting Choice
The utility of the CPT indices for predicting choice varied greatly across
individual indices, vulnerable populations and dose comparisons. Intensity and
Elasticity, when tested separately, significantly predicted choice. While the predictive
utility of Intensity and Elasticity depended on which dose comparisons were being
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analyzed within each vulnerable population, Elasticity was the most consistent predictor
of choice across populations. Among all three populations, the less sensitive to price
(inelastic), the more often a dose was chosen. This suggests that doses which are
relatively less sensitive to environmental constraints are more likely to be preferred in a
concurrent choice paradigm when two doses are available at equal response costs. It is
possible that the other CPT indices, Pmax, Breakpoint and Omax, which were not significant
predictors of choice, do not isolate the reinforcing effects of a drug and instead capture
individual differences related to the greatest costs an individual is willing to incur (e.g.,
Murphy et al., 2012, Dahne et al., 2017, O’Connor et al., 2014). These features may be
more relevant to an individual’s cigarette use history and less relevant to the acute
reinforcing effects of a drug. This question has not been tested directly but certainly
warrants additional scientific attention.
As already noted, the relationships between Elasticity, Intensity and choice varied
depending on dose comparison and/or vulnerable population. Among opioid-maintained
individuals, dose comparisons which had the smallest dose discrepancies (e.g., 0.4 vs. 2.4
and 2.4 vs. 5.2), showed less consistent predictive utility of Elasticity for choice.
Furthermore, Intensity, while predictive of choice among socioeconomically
disadvantaged women of childbearing age and individuals with affective disorders, was
not predictive of choice among opioid-maintained individuals. These population
differences may be a function of the sensitivity of the CPT for detecting individual
differences, which is not as frequently observed in mCEQ or choice preference (e.g.,
Higgins et al., 2018, Cappelleri et al., 2007). For example, our group recently showed
that among vulnerable population smokers, the Heaviness of Smoking Index (a measure
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of cigarette dependence) corresponds to differences in CPT indices but not mCEQ
subscales or concurrent choice preference across a range of doses (Figure 4-1).
Specifically, smokers with higher dependence severity had greater Intensity (Q0) and
Maximum Expenditure (Omax). One component of the HSI is cigarettes smoked per day;
given that Q0 and Omax correspond to this measure of dependence, it perhaps is not
surprising that these two indices differentiated among different levels of dependence. In
addition, as outlined in the Introduction, the CPT is predictive of many measures of the
natural history of smoking (cigarettes per day, nicotine dependence, quit attempts,
clinical outcomes). Therefore,
beyond assessing acute effects of
cigarettes which vary in nicotine
and predicting choice, the CPT also
characterizes individuals with
varying patterns of cigarette use.
So far, it is unclear how
different indices may correspond to
unique aspects of addiction. There
is evidence that all five indices can

Figure 4-1 Demand curves derived from the CPT by
Heaviness of Smoking Index (HSI) scores. Adapted
from “Higgins, S. T., Bergeria, C. L., Davis, D. R.,
Streck, J. M., Villanti, A. C. … Miller, M. E. (2018)
Response to reduced nicotine content cigarettes
among smokers differing in tobacco dependence
severity. Preventive Medicine, In press.

serve as predictors of cigarettes smoked per day, nicotine dependence and
psychopathology (Dahne et al. 2017, Murphy et al., 2012; Secades Villa et al., 2016,
2017). Our data, however, isolates Elasticity as a good measure for detecting acute
relative reinforcing effects regardless of population, which distinguishes the utility of this
index from the other four.
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4.3. Evaluating the Best Self-Report Predictor of Choice
Satisfaction and Enjoyment of Respiratory Tract Sensations, but not Elasticity,
remained predictive of concurrent choice SA. This suggests that the mCEQ subscales are
best at capturing acute relative reinforcing effects of cigarettes concurrently available at
equal response costs. The CPT incorporates how intensity of demand and sensitivity to
environmental constraints influence the reinforcing properties of cigarettes which vary in
nicotine content. While Elasticity was predictive of concurrent choice SA when tested
individually, mCEQ subscales more accurately captured the component of abuse liability
measured in concurrent testing. That said, increasing evidence suggests that the CPT is
best for capturing unique features of abuse liability related to cigarette smoking in
naturalistic settings where environmental constraints are ever present and smoking rates
vary across subpopulations.
4.4. Limitations and Future Directions.
While our analyses provide a more rigorous evaluation of the mCEQ subscales and
CPT indices for evaluating the acute reinforcing effects of smoking, our results should be
considered in light of some limitations.
First, while concurrent choice SA is a laboratory proxy for drug taking, a more
thorough validation of the mCEQ and CPT would be to analyze how these measures
correspond to rates of use outside of the laboratory. Therefore, the clinical utility of
Satisfaction, Enjoyment of Respiratory Tract Sensations and Elasticity should be
interpreted with caution until there is broader validation.
Second, it is unclear how well the relationships between these mCEQ and CPT and
SA data extend to other tobacco products. According to a study by Stein and colleagues
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(2017), the relationship between CPT indices and SA functioned differently depending on
the tobacco product being assessed and perhaps how familiar the participant is with a
product (cigarettes v. snus or nicotine gum). On the other hand, other studies have found
evidence of consistencies across tobacco products when evaluating the relationship
between subjective effects and SA (Arger et al., 2017; Hatsukami et al., 2013c; Perkins et
al., 1996; 1997; 2018).
Together, these limitations provide clear future directions for assessing how
subjective effects and purchase tasks may be related to behavioral assessments of abuse
liability.
4.5. Conclusions
This study compared widely used measures for abuse liability and how well they
assess relative reinforcing efficacy assessed in a concurrent choice SA paradigm. All
three measures provide unique insights into how cigarettes with varying levels of nicotine
may maintain smoking behavior. Concurrent choice testing quantifies the acute relative
reinforcing effects observed with direct drug taking, mCEQ subscales characterize the
positive and negative reinforcing features of cigarette smoking, and the CPT shows how
intensity of demand and environmental constraints influence the abuse liability of
cigarettes which vary in nicotine content. Together these data provide clarity with regard
to the individual components of the mCEQ and CPT that best describe abuse liability in
cigarettes which vary in nicotine content. Furthermore, these methods (behavioral and
self-report) capture unique facets of the abuse liability of cigarettes which vary in
nicotine content. When all three measures are used together, researchers will be better
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able to comprehensively describe the abuse potential of cigarettes with varying levels of
nicotine across unique populations and within unique contexts.
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